BioCentury | Dec 22, 2020
Regulation

Dec. 21-23 Regulatory Quick Takes: positive CHMP opinion for Pfizer-BioNTech COVID-19 vaccine; plus Urovant’s approval, a Feb. 9 adcomm for Keytruda in TNBC, NMPA reviewing a subcutaneous PD-L1, and more

...diagnosis of hepatocellular carcinoma” in one patient. FDA approves Tagrisso in adjuvant NSCLC settingFDA approved Tagrisso osimertinib...
BioCentury | Dec 15, 2020
Deals

In $39B deal, AZ looks to grow rare disease business while Alexion’s investors gain value recognition

...$3.2 billion in sales for cancer therapy Tagrisso osimertinib...
BioCentury | Dec 9, 2020
Emerging Company Profile

How D3 Bio is building its biomarker-driven pipeline

...submissions, including for the EGFR inhibitor Tagrisso osimertinib...
BioCentury | Nov 10, 2020
Regulation

Label expansions coming at a rapid clip for Foundation’s blood-based companion cancer diagnostic

...exon 21 L858R substitution in NSCLC patients for treatment with AZ’s Iressa gefitinib or Tagrisso osimertinib...
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

...cancer therapies including the EGFR inhibitor Tagrisso osimertinib...
...very strong in targeting tumor drivers. That’s your Tagrisso...
BioCentury | Oct 2, 2020
Finance

Next stop IPO? Olema adds to momentum with $85M series C

...pharma gained FDA approvals of PD-L1 inhibitor Imfinzi durvalumab, PARP inhibitor Lynparza olaparib, and Tagrisso osimertinib...
BioCentury | Sep 23, 2020
Product Development

Immunomedics data point to Trodelvy’s $21B potential

...In 45 patients treated in the second-line setting after progressing on blockbuster EGFR inhibitor Tagrisso osimertinib...
...comparison trial with Tagrisso in treatment-naïve patients. AstraZeneca reported nearly $3.2 billion in revenue from Tagrisso...
...signal transducer 2 Lauren Martz Trodelvy, sacituzumab govitecan (hRS7-SN-38, IMMU-132) AMG 160 Tagrisso (Brand), AZD9291 (Compound #), osimertinib (Generic), Tagrisso...
BioCentury | Sep 18, 2020
Management Tracks

Former AZ CMO Bohen brings his cancer chops to Olema

...2019, the pharma had FDA approvals of PD-L1 inhibitor Imfinzi durvalumab, PARP inhibitor Lynparza olaparib, and Tagrisso osimertinib...
...could allow the therapy to treat breast cancer that has metastasized to the brain. He said Tagrisso’s...
...ErbB2; neu) - Epidermal growth factor receptor 2 Danielle Golovin OP-1250 Tagrisso (Brand), AZD9291 (Compound #), osimertinib (Generic), Tagrisso...
BioCentury | Aug 7, 2020
Regulation

Guardant’s liquid biopsy approval paves the way for broader adoption of solid tumor profiling

...comprehensive genomic profiling of solid tumors and as a companion diagnostic for EGFR inhibitor Tagrisso osimertinib...
BioCentury | Jun 23, 2020
Regulation

FDA pilot project aims to provide symptom data to cancer patients

...on a pilot basis with a website presenting information from a trial that compared Tagrisso osimertinib...
Items per page:
1 - 10 of 124